SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Clinuvel Pharmaceuticals Ltd -- Ignore unavailable to you. Want to Upgrade?


To: caly who wrote (6)2/13/2005 8:29:06 PM
From: caly  Read Replies (1) | Respond to of 52
 
EpiTan files for full international patent for sustained release

EpiTan Limited (ASX: EPT, ADR: EPTNY, XETRA: UR9) today announced that it has filed for a full international patent through the Australian Patent Office. The patent application follows discoveries from preliminary data obtained in recent clinical trials of Melanotan ® . The unexpected results relate to the increased efficacy of Melanotan when given at significantly lower dose levels in a sustained manner.

The patent was filed to protect the use of Melanotan in all anticipated sustained release delivery formulations, including implant, topically, orally (a pill) or other. EpiTan's intellectual property counsel confirmed that if this patent application is granted, EpiTan is likely to have 20 years of commercial exclusivity for Melanotan, in sustained release delivery methods. Previously Melanotan has been delivered as a daily bolus injection which required significantly higher quantities of drug. EpiTan has discovered that improved efficacy is obtained with a much lower dose when Melanotan is delivered using a sustained release formulation.

About EpiTan

EpiTan Limited is a Melbourne-based specialty pharmaceutical company with a focus on niche prescription dermatology products. Its leading drug candidate Melanotan ®stimulates the body to make melanin, the dark pigment of a tan which is known to protect the body from skin damage as a result of exposure to ultra-violet (UV) radiation.